



Research Article

SYNTHESIS AND PRELIMINARY ANTICANCER STUDY OF 5-FLUOROURACIL-PHTHALIMIDE CONJUGATE UTILIZING MOLECULAR HYBRIDIZATION APPROACH

Mohammed Hassan Mohammed ^{1*}, Farooq Omer ²

¹Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Baghdad, Iraq

²Ministry of health Iraq

*Corresponding Author Email: dr.mhassanm666666@yahoo.com

Article Received on: 28/09/18 Approved for publication: 22/10/18

DOI: 10.7897/2230-8407.0911252

ABSTRACT

Cancer is still the most challenging disease in the entire world. Molecular hybridization is very interesting approach in design of drug and development depends on the combination of pharmacophoric moieties of two pharmacologically active compounds results in a new hybrid compound with better affinity and efficacy, when compared to the parent drugs. The aim of the present study is to synthesize new 5-fluorouracil derivatives as probable more active anticancer agents than the parent drug. 5-fluoro-4-oxo-1,4-dihydropyrimidin-2-yl2-(1,3-dioxoisindolin-2-ylamino) acetate [IV] and 2-(2-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-oxoethylamino) isoindoline-1,3-dione [V] have been synthesized utilizing hybridization approach from 5-fluorouracil and phthalimide through amino acetate or 2-oxoethylamino linkers. The structures of the newly synthesized compounds and their intermediates were characterized by FT-IR, ¹³C-NMR ESI-MS spectral analysis. A preliminary cytotoxicity study that evaluated by crystal violet assay using a target breast cancer cell, murine mammary adenocarcinoma cell line indicates that the compounds have considerable anticancer activity relative to the lead one.

Keywords: 5-Fluorouracil, Phthalimide, Molecular hybridization

INTRODUCTION

The molecular hybridization (MH) is a strategy of rational design of new ligands or prototypes based on the recognition of pharmacophoric sub-unities in the molecular structure of two or more known bioactive derivatives which, through the adequate fusion of these sub-unities, lead to the design of new hybrid architectures that maintain pre-selected characteristics of the original templates¹. The selection of the pharmacophores or chemical moieties is based upon their known bioprofiles, and it is expected that the molecular hybridization might exhibit synergistic or additive pharmacological activities. Hybrid compounds can be constructed by linking pharmacophore subunits directly or through spacer units. The simple association of two distinct active principles can also be considered a hybrid compound². The hybridization process is closely related to the strategy of obtaining a mutual prodrug, with the main difference being that the prodrug action is dependent on its in vivo cleavage while hybrid compounds can also act like it at their specific receptors or targets². Cancer is a complex disease; it is unlikely that a single mono functional 'targeted' drug will be effective for treating this advanced disease. Combined drugs/active group(s) that impact multiple targets simultaneously are better at controlling complex disease systems, less prone to drug resistance and are the standard of care in cancer treatment. In order to improve the efficiency of using a two-drug cocktail, one approach involves the use of the so-called hybrid drugs³. Several compounds were synthesized depending on the molecular hybridization approach such; mitoxantrone- alkylating agent conjugate⁴, 5-fluorouracil- propafenone conjugate⁵ and Curcumin and Thalidomide⁶.

Thalidomide was introduced in the pharmaceutical market in 1956 by the German Pharmaceutical industry Chemie Grunenthal. A drug was withdrawn from the market due to its

teratogenic effects⁷. Later several studies proved the anticancer activity of thalidomide and these activities can be attributed to its immunomodulatory action, inhibition of angiogenesis, peptidase inhibition, glucosidase inhibition, cyclooxygenase inhibition, pro-apoptotic action and T-cell co-stimulation⁸⁻¹⁰. Several research groups have now developed thalidomide analogues to improve the pharmacodynamic and pharmacokinetic properties, and thereby reducing the teratogenic effects. The design of new thalidomide analogues devoid of teratogenicity resulted from studies demonstrating that the teratogenic effects are due to the toxicophore glutarimide subunit¹¹ as shown in figure 1.




Figure 1: The structure of Phthalimide with glutarimide moiety

The conjugation of phthalimide with other pharmacologically active compounds will lead to improving the pharmacodynamics and pharmacokinetic activity such as anti-asthma activity¹², anti-*Mycobacterium tuberculosis* activity¹³, NF- α inhibitor/NO donor

for the treatment of sickle cell disease symptoms¹⁴ and anti-inflammatory activity¹⁵. In this study, two compounds will be synthesized depending at molecular hybridization approach by conjugation of 5-fluorouracil with phthalimide using 2-aminoacetic acid as the spacer.

MATERIAL AND METHODS

All chemicals and solvents were of annular type and generally used as received from the commercial suppliers (Merck, Germany, Reidel-De Haen, Germany, Sigma-Aldrich, Germany and BDH, England) Melting points were determined by capillary method on Bamstead/ Electrothermal 9100 an Electric melting point apparatus (England), FT-IR spectra (KBr) were recorded on Shimadzu FT-R-8400S spectrophotometer, the mass spectra were obtained by using LC-MS systems and a GC-MS (USA) and ¹³C-NMR spectra measured with Bruker LC-1800 Line NMR using tetramethylsilane as an internal standard. The chemical shifts are expressed in ppm δ scale.

Synthesis of N-aminophthalimide [I]

Phthalic anhydride 5 g (0.033 mol) was dissolved in 100 mL of ethanol. The solution was cooled (ice bath) and stirred at 5 °C. Hydrazine (2 mL 0.033 mol) was added drop wise, and the mixture was stirred for 2hs. ice water (200 ml) was added and the product was filtered, and crystallized from ethanol. Percent yield (85%), melting point 199-201° C, IR((cm⁻¹): 3462 and 3330 (N-H) of primary amine, 1748 and 1690 (C=O) of cyclic imide, ¹³C: 128.51-131.41 (Aromatic peaks), 166.83 2(C=O) and ESI-MS for C₈H₆N₂O₂ [M+1]⁺ calculated 163.15; found 163.86.

Synthesis of 2-(1,3-dioxoisindolin-2-ylamino)acetic acid [II]

A mixture of N- aminophthalimide (compound I) 4.2 g (0.026 mol) , Ethyl bromoacetate 6.52 ml (0.026 mol) and triethylamine 3.6 ml(0.26 mol) in ethanol was refluxed for 3 hr .The solution volume was reduced by vacuum and cooled to 18 °C . Then NaOH (2N, 13 ml, 0.026 mole) was added drop wise, with continuous stirring over a period of 30 mints at 18°C stirring was continued at 18°C for additional 3 hr. The reaction mixture was acidified with HCl (2N, 13 ml, 0.026 mmol), then an excess of cold water was added. The precipitated compound was filtered, dried and recrystallized from ethanol to give the compound II. Percent yield (79%), melting point 197-198° C, IR((cm⁻¹): 3280 (N-H) of secondary amine, 2500-3100 (OH) of carboxylic acid, 1748 and 1690 (C=O) of cyclic imide, 1705 (C=O) of carboxylic acid, ¹³C: 43.33 (CH₂) , 128.51-132.77(Aromatic peaks), 167.04 2(C=O) of cyclic imide ,173.52 (C=O) carboxylic acid and the ESI-MS for C₁₀H₆N₂O₄ [M+1]⁺ calculated 220.18; found 221.45.

Synthesis of 2-(1,3-dioxoisindolin-2-ylamino)acetyl chloride [III]

To a cooled solution of compound [II] 5 g, (0.03 mole) in tetrahydrofuran, thionyl chloride 6 ml was added. The solution was stirred for one hr. at room temperature and then refluxed for one h the excess thionyl chloride was removed in a vacuum, and the resulting solid was used without further purification. Analytical samples were recrystallized from petroleum ether (60-80°C) and dichloromethane CH₂Cl₂. Percent yield 68% melting point 82-83 °C, IR((cm⁻¹): 3250 (N-H) of secondary amine, 1780 (C=O) of acyl chloride, 1730 and 1680 (C=O) of cyclic imide, ¹³C: 56.49 (CH₂), 123.68-130.06 (Aromatic peaks), 167.35 2(C=O) of cyclic imide, 182.51(C=O) of acyl chloride and the ESI-MS for C₁₀H₇ClN₂O₃ [M+2]⁺ calculated 238.63; found 240.14.

Synthesis of 5-fluoro-4-oxo-1,4-dihydropyrimidin-2-yl 2-(1,3-dioxoisindolin-2-ylamino)acetate [IV]

Compound [III] (0.03 mole) in 5 ml tetrahydrofuran was added drop wise to the cold solution (0°C) of 5-fluorouracil 3.9 g (0.03 mol) in 5 ml dimethyl formamide with continuous stirring overnight at room temperature. Then cold water was added, and the resulted precipitate was filtered and recrystallized from ethanol give compound [IV]. Percent yield (55%), melting point 270-271 °C, IR((cm⁻¹): 3260 (N-H) of the secondary amine, 3180 (N-H) of the secondary amide, 1730 and 1680 (C=O) of cyclic imide,1700 (C=O) of secondary amide. ¹³C: 43.32 (CH₂), 125.97-131.90 (Aromatic peaks),121.31 (C=C),124.76(C-F), 158.57, 2(C=O), 167.40, 3(C=O) and the ESI-MS for C₁₄H₉FN₄O₅ [M+1]⁺ calculated 332.24; found 333.15.

Synthesis of 2-(2-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-oxoethylamino)isindoline-1,3-dione [V]

Compound [III] (0.03 mole) in 5 ml tetrahydrofuran was added drop wise to the cold solution (0°C) of the sodium salt of 5-fluorouracil 4.6 g (0.03 mole) in 5 ml dimethyl formamide with continuous stirring overnight at room temperature. Then cold water was added, and the resulted precipitate was filtered and recrystallized from ethanol give compound [V]. Percent yield (61%), melting point 254-256°C, IR((cm⁻¹): 3230 (N-H) of secondary amine, 3160 (N-H) of secondary amide, 1750 and 1680 (C=O) of cyclic imide,1730 (C=O)of ester, 1705 (C=O)of secondary amide, ¹³C: 43.33 (CH₂), 143.60 (O-C=N), 127.67--132.77 (Aromatic peaks),121.31 (C=C),136.06(C-F), 167.00 2(C=O), 162.93, (C=O), 173.52 (C=O), and the ESI-MS for C₁₄H₉FN₄O₅ [M+2]⁺ calculated 332.06; found 334.17.

Cytotoxic Activity Study

The preliminary in vitro cytotoxicity study was done at the Iraqi Centre for Cancer and Medical Genetic Research (ICCMGR) using two types of tumor cell lines: primary tumor of a 70 years old Iraqi woman with a histological diagnosis of infiltrating ductal carcinoma (breast cancer cell line AMJ13) , murine mammary adenocarcinoma cell line (AMN3)¹⁶ and one type of normal cell line: rat embryo fibroblast cell line (Ref).¹⁷ They were maintained in growth medium supplemented with 10% fetal calf serum and seeded on micro-titration (96- well plates at a concentration of 1×10⁴ cells/well) and various concentrations of tested compounds (IV and V) were added from (3.125 to 100 µg/ml) prepared by serial two-fold dilutions using maintenance media from stock solution of test sample in triplicate form of each concentration.

The negative control wells contained only the cells with culture media; then the 96-well cell culture plate incubated at 37°C in an incubator supplemented with 5% CO₂ for two different times (48, 72) h. ¹⁸ The cytotoxic activity of compounds was evaluated by crystal violet assay, the optical density of each well was measured by using ELISA (Enzyme Linked Immuno Sorbent Assay) reader at a transmitting wave length on 492 nm. The inhibition rate of cell growth (the percentage of cytotoxicity) was calculated as (A-B)/A ×100, where A is the mean optical density of untreated wells (control), and B is the optical density of treated wells. ¹⁹


Data were analyzed by 2-way analysis of variance with ANOVA. The level of significance (p<0.05) was used for analysis of the results.

RESULT AND DISCUSSION

Synthesis results

The reaction of phthalic anhydride with hydrazine hydrate resulted in the formation of *N*-aminophthalimide compound [I]²⁰, which was reacted with ethyl bromoacetate then treated with sodium hydroxide in cold condition to form *N*-aminophthalimido acetic acid compound [II]^{21,22}. Compound [II] was reacted with

thionyl chloride in dry tetrahydrofuran and refluxed for 1 hour to form compound [III]²³ that was reacted with 5-fluorouracil, or sodium salt of 5-fluorouracil leads to the formation of the targeting compounds (IV and V) respectively^{23,24}. Structures of these compounds were confirmed, using infrared spectroscopy (IR), ¹³C-NMR spectroscopy, ESI-MS, and some physicochemical properties, which are listed with each one of these compounds (I-V), and their synthetic procedures were described in schemes (1).



Scheme 1: Synthesis of compounds (IV and V)

Table 1: The effects of different concentrations of compound IV on the growth of AMJ13, AMN3, and Ref cell lines

Conc. µg/ml	48 hours			72 hours		
	AMJ13	AMN3	Ref	AMJ13	AMN3	Ref
3.125	0.5 (1.3)	5.1 (1.4)	3.6(3.6)	3.3 (2.1)	5.4(2.1)	-2.5 (5.1)
6.25	1.7 (0.9)	6.3 (0.9)	6.1(5.3)	0.9 (1.9)	16.3(2.2)	2.7(2.7)
12.5	10.5(2.4)	13.2(2.7)	7.0(3.5)	1.6 (0.6)	21.6(2.6)	-0.3 (1.1)
25	52.8(8.7)	49.8(6.3)	7.0(2.6)	40.1(1.2)	26.1(1.8)	5.2(2.6)
50	55.9(0.6)	53.9(1.8)	0.0(5.8)	50.1(1.0)	30.9(3.1)	-1.6 (5.5)
100	61.7(0.9)	80.3(1.6)	6.4(3.2)	51.2(4.8)	34.4(3.5)	-2.5 (3.2)
Data presented using mean (standard error mean)						

Note: Control= 0% inhibition. Positive results of the % growth inhibition indicate anti-proliferation. Negative results of the % growth inhibition indicate proliferation.

Table 2: The Post-hoc test of each pair of concentrations of compound IV (columns comparison) showing their p values

Conc. µg/ml	48 hours			72 hours		
	AMJ13	AMN3	Ref	AMJ13	AMN3	Ref
3.125 vs. 6.25	NS	NS	NS	NS	NS	NS
6.25 vs. 12.5	NS	NS	NS	NS	NS	NS
12.5 vs. 25	<0.0001	<0.0001	NS	NS	<0.0001	NS
25 vs. 50	NS	NS	NS	NS	NS	NS
50 vs. 100	NS	0.0002	NS	NS	NS	NS

NS: non-significant

Table 3: The Post-hoc test of each pair of tissue line at a fixed concentration of compound IV (row comparison) showing their p values

Conc. µg/ml	48 hours			72 hours		
	AMJ13 vs. Ref	AMN3 vs. Ref	AMJ13 vs. AMN3	AMJ13 vs. Ref	AMN3 vs. Ref	AMJ13 vs. AMN3
3.125	NS	NS	NS	NS	NS	NS
6.25	NS	NS	NS	NS	NS	NS
12.5	NS	NS	NS	NS	0.004	0.0087
25	<0.0001	<0.0001	NS	<0.0001	0.0061	NS
50	<0.0001	<0.0001	NS	<0.0001	<0.0001	0.0117
100	<0.0001	<0.0001	0.0025	<0.0001	<0.0001	0.0311

Table 4: The effects of different concentrations of compound V on growth of AMJ13, AMN3, and Ref cell lines

Conc. µg/ml	48 hours			72 hours		
	AMJ13	AMN3	Ref	AMJ13	AMN3	Ref
3.125	21.2 (5.1)	4.3 (5.3)	-5.1 (9.2)	30.1 (5.5)	3.8 (1.2)	0.0 (4.8)
6.25	17.6 (2.7)	7.4 (2.8)	0.0 (8.9)	27.2 (4.1)	3.6 (1.9)	0.0 (4.8)
12.5	24.1 (7.7)	36.7 (5.1)	2.5 (2.6)	22.8 (0.6)	28.3 (4.6)	-2.7 (2.8)
25	45.7 (2.0)	66.8 (2.2)	9.1 (7.1)	45.8 (3.1)	67.7 (3.3)	0.0 (4.8)
50	55.5 (1.5)	62.7 (3.5)	2.7 (2.6)	52.6 (1.0)	65.4 (1.6)	2.7 (2.8)
100	62.1 (3.1)	80.6 (3.7)	10.4 (6.8)	63.4 (1.9)	79.3 (3.5)	8.1 (4.8)

Data presented using mean (standard error mean)

Table 5: The Post-hoc test of each pair of concentrations of compound V (columns comparison) showing their p values

Conc. µg/ml	48 hours			72 hours		
	AMJ13	AMN3	Ref	AMJ13	AMN3	Ref
3.125 vs. 6.25	NS	NS	NS	NS	NS	NS
6.25 vs. 12.5	NS	0.0036	NS	NS	0.0003	NS
12.5 vs. 25	NS	0.0026	NS	0.0006	<0.0001	NS
25 vs. 50	NS	NS	NS	NS	NS	NS
50 vs. 100	NS	NS	NS	NS	NS	NS

NS: non-significant

Table 6: The Post-hoc test of each pair of tissue line at fixed concentration for compound V (row comparison) showing their p values

Conc. µg/ml	48 hours			72 hours		
	AMJ13 vs. Ref	AMN3 vs. Ref	AMJ13 vs. AMN3	AMJ13 vs. Ref	AMN3 vs. Ref	AMJ13 vs. AMN3
3.125	0.0027	NS	NS	<0.0001	NS	<0.0001
6.25	NS	NS	NS	<0.0001	NS	<0.0001
12.5	0.0152	0.0001	NS	<0.0001	<0.0001	NS
25	<0.0001	<0.0001	0.0172	<0.0001	<0.0001	0.0003
50	<0.0001	<0.0001	NS	<0.0001	<0.0001	0.0377
100	<0.0001	<0.0001	0.0401	<0.0001	<0.0001	0.0092

Cytotoxicity study results

The cytotoxic activities (cell viability assay) of compounds (IV and V) were evaluated by Crystal violet assay. A set of six concentrations (3.125, 6.25, 12.5, 25, 50 & 100 µg/ml) was prepared for each product. Two cell lines were studied (AMJ-13 passage no. 50, AMN-3 passage no.117, Ref cell lines passage no. 120) at two times of exposure (48, 72 hours). Data were analyzed by 2-way analysis of variance with ANOVA. The level of significance ($p < 0.05$) was used for analysis of the results. The results indicate that significant inhibitory effects appeared in the cancer cell lines (AMJ13 and AMN3) at different concentrations as showed in tables (1 to 6).

CONCLUSION

Two new derivatives of 5-fluorouracil hybridized with phthalimide were synthesized and evaluated for their anticancer activities. The synthesized compounds were characterized and identified by I.R spectra, ^{13}C -NMR study and ESI-MS it was found that all the results showed good agreements with the proposed chemical structures of the synthesized compounds. A preliminary cytotoxicity studies that evaluated by crystal violet assay indicates that the tested compounds have considerable anticancer activity against two cancer cell lines at different concentrations with no significant inhibitory effect of tested compounds on normal cell line.

REFERENCES

1. Cláudio Viegas-Junior¹, Amanda Danuello¹, Vanderlan da Silva Bolzani¹, Eliezer J. Barreiro² and Carlos Alberto Manssour Fra. Molecular Hybridization: A Useful Tool in the Design of New Drug Prototypes. *Current Medicinal Chemistry* 2007; 14, 1829-1852.
2. Priscila Longhin Bosquesi, Thais Regina Ferreira Melo, Ednir Oliveira Vizioli, Jean Leandro dos Santos and Man Chin Chung. Anti-Inflammatory Drug Design Using a Molecular Hybridization Approach. *Pharmaceuticals*, 2011; 4 1450-1474.
3. Lalji K Gediya and Vincent CO Njar. Promise and challenges in drug discovery and development of hybrid anticancer drugs. *Expert Opinion on Drug Discovery* 2009; 4, 11.
4. Klaus Pors, Zennia Paniwnyk, Paul Teesdale-Spittle, Jane A. Plumb, Elaine Willmore, Caroline A. Austin, and Laurence H. Patterson. Alchemix: A Novel Alkylating Anthraquinone with Potent Activity against Anthracycline- and Cisplatin-resistant Ovarian Cancer. *Molecular Cancer Therapeutics* 2003; 2, July 607-610.
5. Singh P, Paul K. Studies of interactions between uracil-based hybrid molecules and P-glycoprotein-search for multidrug resistance modulators. *Bioorg Med Chem.* 2006; 14(21) 7183-6)
6. Liu, K.; Zhang, D.; Chojnacki, J.; Du, Y.; Fu, H.; Grant, S.; Zhang, S. Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myeloma. *Org. Biomol. Chem.* 2013; 11, 4757-4763.
7. Tseng, S.; Pak, G.; Washenik, K.; Pomeranz, M.K.; Shupack, J.L. Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses. *J. Am. Acad. Dermatol.* 1996; 35, 969-979.
8. Marilyn T. Miller and Kerstin Strohm. Teratogen Update Thalidomide: A Review, With a Focus on Ocular Findings and New Potential Uses. *Teratology* 1999; 60, 306-321.
9. Jeanny B. Aragon-Ching¹, Haiqing Li², Erin R. Gardner³, and William D. Figg, W. Thalidomide Analogues as Anticancer Drugs. *Recent Pat Anticancer Drug Discov.* 2007; 2(2), 167-174.
10. Yeh, C.; Linp.; Hwang, J.; Su, C. Yeh; Yang, ; Chou, M. Study on synthesis of thalidomide analogues and their bioactivities; inhibition on iNOS pathway and cytotoxic effects 2011; 21, 953-963.
11. Lima, L.M.; Fraga, C.A.M.; Barreiro, E.J. O renascimento de um fármaco: Talidomida. *Quim. Nova* 2001; 24, 683-688.
12. Lima, L.M.; Castro, P.; Machado, A.L.; Fraga, C.A.M.; Lugnier, C.; Moraes, V.L.G.; Barreiro, E.J. Synthesis and anti-Inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues. *Bioorg. Med. Chem.* 2002; 10, 3067-3073.
13. Santos, J.L.; Yamasaki, P.R.; Chung, M.C.; Takashi, C.H.; Pavan, F.R.; Leite, C.Q. Synthesis and in vitro anti Mycobacterium tuberculosis activity of a series of phthalimide derivatives. *Bioorg. Med. Chem.* 2009; 17, 3795-3799.
14. Dos Santos, J.L.; Lanaro, C.; Lima, L.; Gambero, S.; Franco-Penteado, C.F.; Alexandre-Moreira, M.S.; Wade, M.; Yorigenahally, S.; Kutlar, A.; Meiler, S.E.; et al. Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. *J. Med. Chem* 2011; 54, 5811-5819.
15. Santos, J.L.; Oliveira, E.V.; Chung, M.C.; Menegon, R.F.; Blau, L. Derivados Ftalimídicos de Compostos Antiinflamatórios Não-Esteróide e/ou Moduladores de TNF-, Processo de sua Obtenção, Composições Farmacêuticas Contendo os Mesmos e Seus Usos no Tratamento de Doenças Inflamatórias” Depositada em 06 de Abril de 2009, INPI 020090033479.
16. Al-Khafaji. A. S., Al-Shamery A. M. H., Subhi. F., Photodynamic action of low power He- Ne laser on photosensitized human Hep-2 and AMN3 cell lines with Hematoporphyrin derivative in vitro. *Iraqi Journal of Cancer and Medical Genetics* 2010; 3, 54-60.
17. Kadhim. H. A. M., Mitochondrial Activity of the Locally Established Rat Embryo Fibroblast Cell Line Through Different Passages, *J Fac Med Baghdad* 2013; 55(2), 182-185.
18. Freshney R.I, Culture of animal cells: A manual for basic technique, 5th ed, John wiley&sons, Inc. publication, NewYork, 2005.
19. Takimoto, C.H., Anticancer drug development at the US National Cancer Institute, *Cancer Chemother. Pharmacol.* 2003; 52, 29-33.
20. Talal H. Zeglam, Omran N. R. Fhid, Suaad M. Abuskhuna, Asma. Gebril, Mohamed. A. Edweshia, Fouad. A. Abonaja¹, Ramy. Y. Krsift, Moad. M. Dardor, Synthesis and Antimicrobial Activity of Some New Phthalimide Derivatives, *Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry* 2015; 3(3), 154 - 161.
21. Yuan Sun, Jonah A. Kaplan, Aileen Shieh, a Hui-Lung Sun, Carlo M. Croce, Mark W. Grinstaff and Jon R. Parquette, Self-Assembly of a 5-Fluorouracil-Dipeptide Hydrogel, *The Royal Society of Chemistry* 2016.
22. Bodansky, M., Klausner, Y.S. and Ondetti, M.A. (Eds). *Peptide Synthesis* (2nd ed.). John Wiley and Sons, New York, 1976.
23. Rajput A.P. and Gore R.P. N-Acylation in non-aqueous and aqueous medium- method of amide synthesis in non-peptide compounds. *Der Pharma Chemica*, 2011; 3, 409-421.
24. Suzuki A.Z., Watanabe T., Kawamoto M., Nishiyama K., Yamashita H. and Ishii M. Coumarin-4-ylmethoxycarbonyls as Phototriggers for Alcohol and Phenols. *ORG LETT.* 2003; 5, 4867-4870.

Cite this article as:

Mohammed Hassan Mohammed and Farooq Omer. Synthesis and preliminary anticancer study of 5-fluorouracil-phthalimide conjugate utilizing molecular hybridization approach. *Int. Res. J. Pharm.* 2018;9(11):26-30 <http://dx.doi.org/10.7897/2230-8407.0911252>

Source of support: Nil, Conflict of interest: None Declared

Disclaimer: IRJP is solely owned by Moksha Publishing House - A non-profit publishing house, dedicated to publish quality research, while every effort has been taken to verify the accuracy of the content published in our Journal. IRJP cannot accept any responsibility or liability for the site content and articles published. The views expressed in articles by our contributing authors are not necessarily those of IRJP editor or editorial board members.